FDA Announces Recall of Lidocaine HCI Injection by Hospira: AttorneyOne Monitor and Keep Consumers Informed

On April 18, the FDA announced that one lot of Lidocaine HCI Injection, USP, by Hospira, is recalled due to visible particulates embedded in the glass vial. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Lidocaine HCI Injection Recall

Lidocaine HCI Injection Recall

Anyone with existing inventory should immediately stop use and quarantine any affected product.

San Diego, CA (PRWEB) April 28, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Lidocaine.

As the FDA announced on April 18, one lot of 1% Lidocaine HCI Injection, USP, 10mg/mL, 30 mL single dose, Preservative – Free, by Hospira, is recalled due to a confirmed customer report of particulate within the solution and embedded within the glass vial that has been identified as iron oxide.

Use of this product, the FDA continues, could lead to local inflammation, and/or mechanical disruption of tissue or immune response to the particulate. Moreover, local granuloma formulation could be caused.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds, “We are determined to keep an eye on FDA announcements concerning drugs and inform the public. For that reason, he continues, "Our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends, “Anyone with existing inventory should immediately stop use and quarantine any affected product. In addition, customers should inform potential users of this product in their organizations of this notification.” And the Agency adds, “Hospira will be notifying its direct distributors/customers via a recall letter and will arrange for impacted product to be returned to Stericycle for returns processing.”

AttorneyOne.com has further information on drugs at the website including latest major drug and medical products law news.

Headquartered in San Diego, CA, Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/04/prweb11795790.htm.